<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of human African trypanosomiasis (HAT) due to &lt;em&gt;Trypanosoma brucei gambiense&lt;/em&gt; in adults and children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of human African trypanosomiasis (HAT) due to <em>Trypanosoma brucei gambiense</em> in adults and children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of human African trypanosomiasis (HAT) due to <em>Trypanosoma brucei gambiense</em> in adults and children</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16.6%"></colgroup> <tbody> <tr> <td class="subtitle1">Patient characteristics</td> <td class="subtitle1">Clinical evaluation and staging</td> <td class="subtitle1">CSF findings</td> <td class="subtitle1">Preferred therapy</td> <td class="subtitle1">Alternative therapy*</td> <td class="subtitle1">Rescue therapy<sup>¶</sup></td> </tr> <tr> <td class="divider_bottom" rowspan="2"><strong>&lt;6 years old or &lt;20 kg body weight</strong></td> <td class="divider_bottom" rowspan="2">Perform lumbar puncture</td> <td>First-stage disease: WBC ≤5 cells/microL and no trypanosomes</td> <td><strong>Pentamidine</strong><sup>Δ</sup>: 4 mg/kg/day IM or IV (infuse over 1 to 2 hours) once daily for 7 days</td> <td>–</td> <td><strong>Nifurtimox-eflornithine combination therapy (NECT):</strong> <ul class="decimal_heading"> <li>Nifurtimox: 15 mg/kg per day orally in 3 doses for 10 days <strong>plus</strong></li> <li>Eflornithine 400 mg/kg per day IV divided every 12 hours (infuse over 2 hours) for 7 days</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Second-stage disease: WBC &gt;5 cells/microL, and/or trypanosomes</td> <td><strong>NECT</strong> (dosing as above)</td> <td><strong>Eflornithine monotherapy:</strong> 100 mg/kg IV every 6 hours for (infuse over 2 hours) 14 days</td> <td><strong>NECT-long:</strong> <ul class="decimal_heading"> <li>Nifurtimox: 15 mg/kg per day orally in 3 divided doses for 10 days <strong>plus</strong></li> <li>Eflornithine 400 mg/kg per day IV divided every 12 hours (infuse over 2 hours) for 14 days</li> </ul> </td> </tr> <tr> <td rowspan="3"><strong>≥6 years old and ≥20 kg body weight</strong></td> <td>If no suspicion for severe disease <sup>◊</sup>, lumbar puncture not needed</td> <td>None</td> <td> <p><strong>Fexinidazole</strong><sup>§</sup> (taken with food)</p> Body weight ≥35 kg: <ul class="decimal_heading"> <li>Loading phase: 1800 mg orally once daily for 4 days</li> <li>Maintenance phase: 1200 mg orally once daily for 6 days</li> </ul> <p> </p> Body weight 20 to &lt;35 kg: <ul class="decimal_heading"> <li>Loading phase: 1200 mg orally once daily for 4 days</li> <li>Maintenance phase: 600 mg orally once daily for 6 days</li> </ul> </td> <td> <p>Lumbar puncture needed<sup>¥</sup></p> <p>First-stage disease (WBC ≤5 cells/microL and no trypanosomes): <strong>Pentamidine</strong> (dosing as above)</p> <p>Second-stage disease (WBC &gt;5 cells/microL, and/or trypanosomes): <strong>NECT</strong> (dosing as above)</p> If NECT not available: treat with <strong>eflornithine monotherapy</strong> (dosing as above)</td> <td><strong>NECT</strong> (dosing as above)</td> </tr> <tr> <td rowspan="2">If suspicion<sup>◊</sup> for severe disease, perform lumbar puncture</td> <td>Nonsevere second-stage disease: WBC &lt;100 cells/microL</td> <td><strong>Fexinidazole</strong><sup>§</sup> dosing as above</td> <td> <p>First-stage disease (WBC ≤5 cells/microL and no trypanosomes): <strong>Pentamidine</strong> (dosing as above)</p> <p>Second-stage disease (WBC &gt;5 cells/microL, and/or trypanosomes): <strong>NECT</strong> (dosing as above)</p> If NECT not available: treat with <strong>eflornithine monotherapy</strong> (dosing as above)</td> <td><strong>NECT</strong> (dosing as above)</td> </tr> <tr> <td>Severe second-stage disease: WBC ≥100 cells/microL or unable to perform lumbar puncture</td> <td> <p><strong>NECT:</strong> dosing as above</p> If NECT not available: treat with <strong>eflornithine monotherapy</strong> (dosing as above)</td> <td><strong>Fexinidazole</strong> (dosing as above)</td> <td> <p><strong>NECT-long</strong> (dosing as above)</p> <p><strong>or</strong></p> <strong>Melarsoprol</strong><sup>‡</sup> 2.2 mg/kg/day IV once daily for 10 days (maximum dose: 180 mg)</td> </tr> </tbody></table></div><div class="graphic_footnotes">CSF: cerebrospinal fluid; 
	WBC: white blood cell count; 
	IM: intramuscular; 
	IV: intravenous.<br/>
	
	* Alternative treatment should be given in cases where the preferred treatment is not available or not appropriate for a particular patient.<br/>
	
	¶ Rescue treatment is given in cases of treatment failure with a preferred or alternative agent.<br/>
	
	Δ Pentamidine is usually given as an IM injection because IV administration is frequently associated with severe hypotension. Patients should lie down for at least one hour after injection to prevent hypotension and should eat or drink sugar to prevent hypoglycemia. Monitor vital signs before and 1 hour after administration (and continue if hemodynamic instability). Electrocardiogram and serum glucose monitoring should be considered when feasible.<br/>
<span class="lozenge">◊</span> Refer to separate table summarizing symptoms and signs raising suspicion for severe disease.<br/>
	
	§ Fexinidazole should be administered only if there is high confidence that the patient will have appropriate follow up to detect relapse early. Concomitant food intake is required for adequate absorption. Outpatient treatment is possible under certain conditions; refer to text for further discussion.<br/>
	
	¥ If fexinidazole cannot be given, lumbar puncture is required to determine therapy.<br/>
	
	‡ Melarsoprol may be used as an agent of last resort for patients with recurrent relapse of second-stage gambiense HAT following first-line and rescue treatments (including NECT, NECT-long, fexinidazole, or eflornithine monotherapy). Melarsoprol is associated with high frequency of severe, life-threatening adverse effects and should be coadministered with prednisolone 1 mg/kg per day orally once daily (maximum dose: 50 mg) for 9 days, followed by a 3-day taper (day 10: 0.75 mg/kg; day 11: 0.5 mg/kg; day 12: 0.25 mg/kg). Melarsoprol should not come into contact with water due to risk of precipitation. Care must be taken if using plastic syringes; after drawing up the liquid, it must be administered immediately but slowly. Refer to UpToDate text for further discussion.</div><div class="graphic_reference">Adapted from: WHO interim guidelines for the treatment of gambiense human African trypanosomiasis, August 2019. World Health Organization 2019. Available at: <a href="https://apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf" target="_blank">https://apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf</a> (Accessed on December 10, 2021).</div><div id="graphicVersion">Graphic 130335 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
